BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Letter to Stockholders

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today released a letter to stockholders from its Chief Executive Officer Dr. James Woody. In the letter, Dr. Woody discussed the company’s continued status to remain on track with clinical development plans. “Currently, we have an active clinical development program that includes phase 2a and phase 2b proof-of-concept data, which we believe demonstrates that anti-TNF therapy can prevent the progression of Dupuytren’s disease in its early stages, as well as plans for two additional phase 2 studies, one in frozen shoulder, which has recently commenced, and the other in post-operative cognitive delirium (‘POCD’), for which we just received grant funding,” Dr. Woody stated in the letter. “In closing, we continue to work diligently and efficiently to deliver treatment options for one of the largest drivers of disease, inflammation. Our active clinical development program currently consists of three potential indications and our clinical development plans for all ongoing programs remain on track. We believe that the successful execution of our current clinical development plans over the long-term could enhance stockholder value.”

To view the full press release, visit https://ibn.fm/MgGLo

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company driving groundbreaking studies into clinical programs, which are seeking to address major unmet clinical needs. The company’s primary platform is a novel program to treat inflammatory disorders using anti-TNF (tumor necrosis factor). For more information, visit the company’s website at www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork